StockData
Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc. (RCUS) stock

RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30123% above fair value
$15.76−0.63 (-3.84%)

Close on Nov 18, 2026Market cap $2.01BP/E –Yield –

Earnings

Arcus Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$9.00M
-65.4% on a year earlier
EPS, Q3 FY2026
-$1.00
-$1.27 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Arcus Biosciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$9.00M-65.4%-$1.00Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$41.00M-74.4%-$0.72Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours$17.00M-39.3%-$1.02Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026during market hours$33.00M-8.3%-$0.89Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025during market hours$26.00M-45.8%-$1.27Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$160.00M+310.3%–Release
Q1 FY2025ended Mar 31, 2025May 6, 2025during market hours$28.00M-80.7%-$1.14Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025during market hours$36.00M+16.1%-$1.03Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours$48.00M+50.0%–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$39.00M+34.5%-$1.02Release
Q1 FY2024ended Mar 31, 2024May 8, 2024during market hours$145.00M+480.0%-$0.05Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Arcus Biosciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
GAAP revenueGAAPFY2026$70.00M – $75.00M–NewNov 4, 2026
GAAP revenueGAAPFY2026$65.00M – $75.00M$50.00M – $65.00MRaisedAug 5, 2026
cashFY2026$600.00M–NewAug 5, 2026

Guidance vs results

The last range Arcus Biosciences gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$225.00M – $235.00M$247.00MΣ4QAbove range

Guidance history

Every forecast Arcus Biosciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026GAAP revenueFY2026$70.00M – $75.00MNew
Aug 5, 2026cashFY2026$600.00MNew
Aug 5, 2026GAAP revenueFY2026$65.00M – $75.00MRaised
May 5, 2026GAAP revenueFY2026$50.00M – $65.00MRaised
Feb 25, 2026GAAP revenueFY2026$45.00M – $55.00MNew
Oct 28, 2025GAAP revenueFY2025$225.00M – $235.00MNew
Aug 6, 2025GAAP revenueFY2025$225.00M – $235.00MRaised
May 6, 2025GAAP revenueFY2025$75.00M – $90.00MNew
Nov 6, 2024Cash, cash equivalents and marketable securitiesFY2024$950.00M – $985.00MRaised
Aug 8, 2024Cash, cash equivalents and marketable securitiesFY2024$885.00M – $925.00MRaised
May 8, 2024Cash, cash equivalents and marketable securitiesFY2024$870.00M – $920.00MReaffirmed
Feb 21, 2024Cash, cash equivalents and marketable securitiesFY2024$870.00M – $920.00MNew
Nov 7, 2023cash utilizationFY2023$265.00M – $290.00MLowered
Aug 7, 2023cash utilizationFY2023$290.00M – $325.00MLowered
Feb 28, 2023cash utilizationFY2023$300.00M – $350.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Arcus Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. News
  12. Results
  13. Results
  14. News
  15. Results

See a number that looks wrong?